Total Funding
90
89
Total FundingPost-IPO Equity raised
Growth Score
-7 pts
Heat Score
23 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
20162
Elicera Therapeutics develops cell and gene therapies for cancer treatment, with a focus on CAR T-cell therapies and oncolytic viruses.
About the Company
Elicera Therapeutics develops cell and gene therapies for cancer treatment, with a focus on CAR T-cell therapies and oncolytic viruses. The company operates a proprietary technology platform called iTANK, which is designed to enhance immune responses in cancer therapies and support the development of treatments for aggressive and relapsing cancers.
Its pipeline includes immunotherapy candidates for blood cancers, solid tumors, and neuroendocrine tumors, alongside research programs aimed at improving the effectiveness of CAR T-cell therapies. Elicera Therapeutics also collaborates with pharmaceutical and biotechnology companies through licensing opportunities related to its iTANK platform and therapeutic technologies.
